# Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

> **NCT05520723** · PHASE2 · COMPLETED · sponsor: **MedSIR** · enrollment: 50 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Breast Cancer
- Advanced HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Loperamide
- **DRUG:** Granulocyte Colony-Stimulating Factor

## Key facts

- **NCT ID:** NCT05520723
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-06
- **Primary completion:** 2023-10-18
- **Final completion:** 2025-11-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05520723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05520723, "Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05520723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*